Clinical Trial Update: Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study evaluated escalating intravenous doses of INA03 as a single agent in adults with relapsed or refractory acute leukemias, including acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• INA03

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse | EARLY_Phase 1 | Status: COMPLETED